CMS will reimburse providers $502 per test. The payment decision follows a joint FDA and CMS review pilot program. Cologuard became the first technology to gain approval through this process.
“CMS’ final payment decision represents a major milestone by providing 50 million Medicare patients access to this noninvasive colorectal cancer screening option,” said Kevin Conroy, president, CEO and chairman of Exact Sciences.
More articles on gastroenterology:
What can GI physicians do to boost GERD awareness?
Financial leadership playbook: The essential skills for a CFO in gastroenterology
Higher Medicaid reimbursement associated with higher cancer screening rates
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.